Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.50 |
| ▸ | FDPS | P14324 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14384380 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL2573740 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL8513608 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL13819798 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL13538692 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL13819793 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL574092 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL7912103 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL11386622 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 | |
| SCHEMBL12154896 | 1.00 | CA1 (0.61) | CA1ACE2GPR84FDPSFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9433577-B2 | Pharmaceutical composition comprising oligopeptides | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20120288539-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES | MERCK PATENT GMBH (DE) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288539-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OLIGOPEPTIDES | VIP, LNPEP, IAPP | CA1 2312/4885ACE2 335/4885GPR84 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.